GLP1R and Alzheimer disease: ISAP is a randomised, double-blind, placebo-controlled parallel-group, superiority trial of oral semaglutide given over a period of 12 months that aims to clarify the mechanism through which GLP-1 RAs may impact AD pathophysiology.